Mitsubishi UFJ Trust & Banking Corp Decreases Position in Glaukos Corp (GKOS)

Mitsubishi UFJ Trust & Banking Corp lowered its stake in Glaukos Corp (NYSE:GKOS) by 1.6% during the third quarter, Holdings Channel reports. The institutional investor owned 230,850 shares of the medical instruments supplier’s stock after selling 3,640 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Glaukos were worth $14,982,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in shares of Glaukos by 10.2% during the 1st quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock worth $918,000 after purchasing an additional 2,746 shares during the period. Xact Kapitalforvaltning AB purchased a new position in shares of Glaukos during the 2nd quarter worth $248,000. Bank of Montreal Can purchased a new position in shares of Glaukos during the 2nd quarter worth $1,497,000. Amalgamated Bank acquired a new position in Glaukos during the 2nd quarter worth about $205,000. Finally, Wells Fargo & Company MN lifted its stake in Glaukos by 19.3% during the 2nd quarter. Wells Fargo & Company MN now owns 311,507 shares of the medical instruments supplier’s stock worth $12,660,000 after acquiring an additional 50,403 shares in the last quarter.

In other news, Director William J. Phd Link sold 14,475 shares of the stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $58.01, for a total value of $839,694.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $60.03, for a total value of $300,150.00. Following the completion of the transaction, the chief financial officer now owns 86,117 shares in the company, valued at approximately $5,169,603.51. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,075 shares of company stock worth $3,653,652. Company insiders own 11.60% of the company’s stock.

GKOS has been the topic of several research reports. Stephens reissued an “overweight” rating and set a $57.00 target price on shares of Glaukos in a research note on Wednesday, August 29th. BMO Capital Markets increased their target price on Glaukos from $59.00 to $62.00 and gave the stock a “market perform” rating in a research note on Thursday, August 30th. Zacks Investment Research raised Glaukos from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research note on Tuesday, August 7th. Berenberg Bank initiated coverage on Glaukos in a research note on Thursday, August 30th. They set a “hold” rating and a $57.00 target price on the stock. Finally, ValuEngine raised Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $58.20.

GKOS stock opened at $67.93 on Tuesday. Glaukos Corp has a 1 year low of $23.08 and a 1 year high of $70.91.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $43.91 million during the quarter, compared to analyst estimates of $41.65 million. Glaukos had a negative net margin of 8.13% and a negative return on equity of 9.26%. Glaukos’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 EPS. As a group, analysts anticipate that Glaukos Corp will post -0.55 EPS for the current year.

WARNING: “Mitsubishi UFJ Trust & Banking Corp Decreases Position in Glaukos Corp (GKOS)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/12/04/mitsubishi-ufj-trust-banking-corp-decreases-position-in-glaukos-corp-gkos.html.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Featured Article: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit